1 terminated, 1 withdrawn. 2 Phase 2.
| Phase | Trials | Status |
|---|---|---|
| Phase 2 | 2 | Terminated 1, Withdrawn 1 |
Follow Flotetuzumab: new trials by email Literature Review of Flotetuzumab trials Research Report on Flotetuzumab
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| Study to Assess an Interphase Cycle With Flotetuzumab. Flotetuzumab - AML | Phase 2 | Withdrawn | Stichting Hemato-Oncologie voor Volwassenen Nederland | 2022-01-01 | 2021-12-22 | |
| Flotetuzumab for Relapsed Acute Myeloid Leukemia (AML) and Myelodysplastic Syndrome (MDS) Following Allogeneic Hematopoietic Cell Transplantation (Allo-HCT) Flotetuzumab, Donor lymphocyte infusion - Relapsed Acute Myeloid Leukemia | Phase 2 | Terminated | Washington University School of Medicine | 11 | 2021-05-20 | 2024-12-06 |
Stichting Hemato-Oncologie voor Volwassenen Nederland (1) · Washington University School of Medicine (1)
Netherlands (1) · United States (1)
M. Jongen-Lavrencic, PhD (1) · Matthew Christopher, M.D., Ph.D. (1)
P50CA171963 (1)